Erytech Pharma (NASDAQ:ERYP) Raised to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Erytech Pharma (NASDAQ:ERYP) from a sell rating to a hold rating in a research note published on Wednesday, reports.

According to Zacks, “Erytech Pharma S.A. operates as a biopharmaceutical company. It discovers and developes therapies for rare forms of cancer and orphan diseases. The company’s product pipeline consists of eryaspase, erymethionase, eryminase, ERYZYME and ERYMMUNE which are in clinical stages. It operates primarily in France and the United States. Erytech Pharma S.A. is based in France. “

Separately, ValuEngine downgraded shares of Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd.

NASDAQ ERYP opened at $6.67 on Wednesday. Erytech Pharma has a 52-week low of $5.45 and a 52-week high of $11.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.26 and a quick ratio of 7.19. The company has a market cap of $119.66 million, a P/E ratio of 2.73 and a beta of 1.51. The stock’s fifty day moving average is $6.90.

Erytech Pharma Company Profile

ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.

Further Reading: The primary rules of Elliott Wave theory

Get a free copy of the Zacks research report on Erytech Pharma (ERYP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with's FREE daily email newsletter.